Doxorubicin (DOX) is used in the treatment of cancer. However, cardiotoxicity is its major dose-limiting factor. Mechanism of DOX–cardiac toxicity is not completely elucidated. The aim of the current study was to explore whether the addition of subeffective dose of curcumin (100 mg/kg) to nebivolol would produce a better impact in treating DOX-induced cardiac toxicity in comparison with monotherapy. Male rats were used and subdivided into seven groups. Cardiac toxicity was induced in 6 groups by intraperitoneal injection of DOX over 23 days; of the six groups, five groups were treated with curcumin (100 and 200 mg/kg), nebivolol (1 and 2 mg/kg), and their combination; the sixth group was the control group used for comparison. Oral administration of curcumin and/or nebivolol attenuated DOX cardiotoxicity as manifested by increasing survival rate, improvement in body weight, heart index, and ECG parameters, increase in ventricular isoprenaline responses, and improvement in cardiac enzymes, oxidative stress, apoptosis, and histopathological picture. The addition of the current low subeffective dose of curcumin to nebivolol ameliorated DOX cardiac toxicity to a much greater extent than monotherapy showing better antioxidant and antiapoptotic effects versus the per se effect of nebivolol. Therefore, the current study encourages adding low dose of curcumin to potentiate the effect of nebivolol in the clinical management of cardiac toxicity improving the patients’ quality of life if proper clinical safety data are available.

No abstract

These data indicate that MNCs treatment was superior to pioglitazone in controlling hyperglycemia, improving the renal structure and function changes and reducing renal laminin expression associated with STZ-induced diabetic nephropathy in rats.

Aim: Oxidative stress has been implicated in the neurological diseases, one of them is epilepsy. Therefore, this study was conducted to determine the effect of vitamin C as an acute antioxidant protective treatment of epilepsy in mice. Materials and Methods: Seventy-eight male albino mice were divided into six groups. The first group was a normal control group that received NaCl, 0.9% (i.p.). The second group received PTZ (65 mg/kg, i.p.) as a single convulsive dose. The third and fourth groups received vitamin C (500 mg/kg/day, i.p.) and vitamin C (1000mg/kg, i.p.) respectively. The fifth and sixth groups received vitamin C (500 mg/kg/day, i.p.) and vitamin C (1000 mg/kg, i.p.) respectively, then after 30 minutes both received Pentylenetetrazole (PTZ) (65 mg/kg i.p.) as a single convulsive dose. Behavioral assessment was done immediately after injections using Racine scale and rotarod tests then after 24 hours, the animals were killed and brain tissue homogenates were prepared to measure lipid peroxide (Malondialdehyde) and catalase activity. Results: Vitamin C showed decreased percentage of seizures, prolonged latency to 1 st seizure, improved motor coordination, decreased lipid peroxide level and increased catalase activity. No difference in results between groups received vitamin C (500 mg/kg, i.p.) or (1000 mg/kg, i.p.). Conclusion: Vitamin C was proven to be a potential candidate for decreasing risk of epilepsy.

No abstract